Literature DB >> 19317758

Need to establish a national diagnostic capacity for foetal alcohol spectrum disorders.

Raewyn Mutch1, Elizabeth M Peadon, Elizabeth J Elliott, Carol Bower.   

Abstract

Alcohol exposure in pregnancy can induce a broad range of physical and developmental defects in the child, collectively known as foetal alcohol spectrum disorders (FASD). In Australia, there are proven gaps in our knowledge and practice for recognising and diagnosing FASD. The challenge for the Australian health professional is agreeing on a model for diagnosing and treating FASD. The diagnostic method must be evidence based, sensitive and specific, and account for other exposures during pregnancy and early life events. Training in application of the diagnostic method needs to be readily available in metropolitan and regional Australia. The University of Washington FASD 4-digit diagnostic code fulfils all of these best practice criteria, recommending itself as the method of choice.

Entities:  

Mesh:

Year:  2009        PMID: 19317758     DOI: 10.1111/j.1440-1754.2009.01464.x

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  7 in total

1.  Patterns of alcohol consumption among pregnant African-American women in Washington, DC, USA.

Authors:  Michele Kiely; Jutta S Thornberry; Brinda Bhaskar; Margaret F Rodan
Journal:  Paediatr Perinat Epidemiol       Date:  2011-04-03       Impact factor: 3.980

2.  Health professionals' perceptions about the adoption of existing guidelines for the diagnosis of fetal alcohol spectrum disorders in Australia.

Authors:  Rochelle E Watkins; Elizabeth J Elliott; Raewyn C Mutch; Jane Latimer; Amanda Wilkins; Janet M Payne; Heather M Jones; Sue Miers; Elizabeth Peadon; Anne McKenzie; Heather A D'Antoine; Elizabeth Russell; James Fitzpatrick; Colleen M O'Leary; Jane Halliday; Lorian Hayes; Lucinda Burns; Maureen Carter; Carol Bower
Journal:  BMC Pediatr       Date:  2012-06-14       Impact factor: 2.125

3.  The Lililwan Project: study protocol for a population-based active case ascertainment study of the prevalence of fetal alcohol spectrum disorders (FASD) in remote Australian Aboriginal communities.

Authors:  James P Fitzpatrick; Elizabeth J Elliott; Jane Latimer; Maureen Carter; June Oscar; Manuela Ferreira; Heather Carmichael Olson; Barbara Lucas; Robyn Doney; Claire Salter; Elizabeth Peadon; Genevieve Hawkes; Marmingee Hand
Journal:  BMJ Open       Date:  2012-05-03       Impact factor: 2.692

4.  Invited commentary on Australian fetal alcohol spectrum disorder diagnostic guidelines.

Authors:  Susan J Astley
Journal:  BMC Pediatr       Date:  2014-04-01       Impact factor: 2.125

5.  Consensus diagnostic criteria for fetal alcohol spectrum disorders in Australia: a modified Delphi study.

Authors:  Rochelle E Watkins; Elizabeth J Elliott; Raewyn C Mutch; Janet M Payne; Heather M Jones; Jane Latimer; Elizabeth Russell; James P Fitzpatrick; Lorian Hayes; Lucinda Burns; Jane Halliday; Heather A D'Antoine; Amanda Wilkins; Elizabeth Peadon; Sue Miers; Maureen Carter; Colleen M O'Leary; Anne McKenzie; Carol Bower
Journal:  BMJ Open       Date:  2012-10-25       Impact factor: 2.692

6.  Development of a reliable questionnaire to assist in the diagnosis of Fetal Alcohol Spectrum Disorders (FASD).

Authors:  James P Fitzpatrick; Jane Latimer; Manuela Ferreira; Alexandra L C Martiniuk; Elizabeth Peadon; Maureen Carter; June Oscar; Emily Carter; Meredith Kefford; Rhonda Shandley; Harry Yungabun; Elizabeth J Elliott
Journal:  BMC Pediatr       Date:  2013-03-07       Impact factor: 2.125

7.  A modified Delphi study of screening for fetal alcohol spectrum disorders in Australia.

Authors:  Rochelle E Watkins; Elizabeth J Elliott; Jane Halliday; Colleen M O'Leary; Heather D'Antoine; Elizabeth Russell; Lorian Hayes; Elizabeth Peadon; Amanda Wilkins; Heather M Jones; Anne McKenzie; Sue Miers; Lucinda Burns; Raewyn C Mutch; Janet M Payne; James P Fitzpatrick; Maureen Carter; Jane Latimer; Carol Bower
Journal:  BMC Pediatr       Date:  2013-01-25       Impact factor: 2.125

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.